Goldstone Financial Group LLC Sells 4,017 Shares of Abbott Laboratories $ABT

Key Points

• Goldstone Financial Group LLC reduced its holdings in Abbott Laboratories by 28.9%, selling 4,017 shares and bringing their total to 9,884 shares. This represents a value of approximately $1.33 million as of the latest SEC filing.
• Insider trading was noted, with CFO Philip P. Boudreau selling 5,550 shares at an average price of $134.55, decreasing his stake by 9.81% to hold 51,003 shares.
• Abbott Laboratories reported $1.26 EPS in its last quarterly earnings, meeting analyst expectations, and outlined a fiscal year 2025 EPS guidance of $5.100-$5.200.

Goldstone Financial Group LLC lessened its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 28.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,884 shares of the healthcare product maker's stock after selling 4,017 shares during the quarter. Goldstone Financial Group LLC's holdings in Abbott Laboratories were worth $1,329,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Cim LLC raised its holdings in Abbott Laboratories by 0.4% in the fourth quarter. Cim LLC now owns 16,967 shares of the healthcare product maker's stock worth $1,919,000 after purchasing an additional 73 shares in the last quarter. Consilium Wealth Advisory LLC raised its holdings in Abbott Laboratories by 2.1% in the first quarter. Consilium Wealth Advisory LLC now owns 3,822 shares of the healthcare product maker's stock worth $507,000 after purchasing an additional 78 shares in the last quarter. Mayflower Financial Advisors LLC raised its holdings in Abbott Laboratories by 0.5% in the first quarter. Mayflower Financial Advisors LLC now owns 17,327 shares of the healthcare product maker's stock worth $2,298,000 after purchasing an additional 78 shares in the last quarter. Opes Wealth Management LLC raised its holdings in Abbott Laboratories by 2.9% in the first quarter. Opes Wealth Management LLC now owns 2,854 shares of the healthcare product maker's stock worth $379,000 after purchasing an additional 80 shares in the last quarter. Finally, Lcnb Corp raised its holdings in Abbott Laboratories by 0.5% in the first quarter. Lcnb Corp now owns 15,917 shares of the healthcare product maker's stock worth $2,111,000 after purchasing an additional 80 shares in the last quarter. Institutional investors own 75.18% of the company's stock.

Insider Activity

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Up 1.0%

Abbott Laboratories stock opened at $133.92 on Monday. The business has a 50-day simple moving average of $130.41 and a two-hundred day simple moving average of $131.25. The company has a market cap of $233.08 billion, a P/E ratio of 16.78, a P/E/G ratio of 2.54 and a beta of 0.69. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ABT shares. BTIG Research reduced their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday, July 18th. Royal Bank Of Canada raised their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and raised their price target for the company from $143.00 to $145.00 in a report on Friday, July 18th. Raymond James Financial reduced their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. Finally, Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $144.47.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.